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extensively studied the role of epigenetics in melanoma, further elucidating the complex processes involved in gene regulation
and expression. Other studies utilizing gene microarray analysis and other whole genome approaches reveal a wide array of
genes and expression patterns in human melanoma. Several genes have been identiﬁed as potential prognostic markers of
tumor progression and overall clinical outcome. High-throughput gene expression analysis has had a major impact in melanoma
research. Several gene expression platforms have provided insight into the gene expression patterns in melanoma. Such data
will provide foundations for the future development of prognostic markers and improved targeted therapies for patients with
melanoma.
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Hidradenitis suppurativa (HS) is a chronic follicular occlusive disease (Hurley grade III and refractory) characterized by abscesses
and draining sinus tracts in apocrine gland-bearing regions. HS is frequently refractory to conventional management with oral
and topical treatments and may require surgical intervention. We report the outcomes of an exploratory study investigating the
effectiveness of radiation therapy for patients with refractory HS who failed multiple other therapies. Ten patients with Hurley
stage III and refractory were treated with radiation therapy to 25 affected sites (axillae, groin, perineal, perianal and infra/inter-
mammary folds). Each area was treated with electron beam radiation to a total dose of 20Gy in 4-5Gy fractions over 4 or 5
consecutive days. The average age was 40 years old and 99% had HS for longer than 5 years. By Hurley stage, 9 were stage III and
one was stage II. All patients previously failed topical and oral antibiotic therapy and other previous therapies included surgery
and inﬂiximab. All patients tolerated radiation well. Complete responses were observed ≥50% of the lesions and ≥90% had a
partial response after radiation therapy determined by patient report and clinical exam. Radiation therapy may be a promising
treatment for some patients with refractory HS. More basic research has to be initiated or strengthened and controlled clinical
multicenter studies have to be conducted not only to conﬁrm basic research data, but also to prove treatment efﬁcacy and
optimize treatment schedules (single and total dose, fractionation, and treatment time).
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Introduction. The expected yearly incidence of melanoma in the province of Cordoba is 51 cases. The optimal irradiation rate
has been estimated as 23% by groups of excellency based on scientiﬁc evidence. Since 2006 the Reina Sofía Hospital has had a
Melanoma Multidisciplinary Tumor Board.
Materials and methods. Descriptive retrospective study of the population of the province of Cordoba with skin melanoma referred
to the Department of Radiation Oncology.
Results. Scientiﬁc evidence shows that 11 patients diagnosed with melanoma per year should receive radiation therapy in the
province of Cordoba, which in 6 years would be 66 patients. During the period 2006–2011 the number of patients diagnosed
with melanoma and presented in the tumor board was 339. Of these patients, 29 (8.5%) were referred to the Department of
Radiation Oncology for evaluation. 58.6% were women. The median age was 71 years. Trunk (37.9%) and lower limbs (27.6%)
were the most frequent locations. Stage distribution was 12% in Stage 1, 48% in Stage II, and 16% and 24% in Stages III and IV
respectively. Surgery was the standard treatment option (89%), resulting in R1 in 76.9%. In 72.7% margins were expanded. The
sentinel node selective biopsy was performed in 26.1%, and resulted positive in 33.3%, provoking regional lymphadenectomy.
Locoregional failure occurred in 72.7%, and distant metastases in 77.3% of patients at the time of analysis. The median relapse
free survival and metastasis free survival were 9 and 26.5 months, respectively. Radiation therapy was administered in 62.1%
of referred patients. It was palliative in 88.9%. The median overall survival of this subgroup was of 25 months. 88% had passed
away at the moment of this study.
Conclusions. The number of patients diagnosed with melanoma referred for radiation treatment evaluation in the province of
Cordoba is inferior to that estimated as optimal.
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